Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) saw unusually-high trading volume on Thursday . Approximately 1,509,609 shares were traded during trading, an increase of 26% from the previous session’s volume of 1,195,256 shares.The stock last traded at $4.97 and had previously closed at $4.92.

PGNX has been the topic of several research reports. Brean Capital reissued a “buy” rating and set a $14.00 price objective on shares of Progenics Pharmaceuticals in a research note on Friday, May 6th. Jefferies Group reissued a “buy” rating on shares of Progenics Pharmaceuticals in a research note on Friday, June 10th. Zacks Investment Research lowered shares of Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. Finally, Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Progenics Pharmaceuticals in a research note on Monday, April 4th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $10.35.

The stock has a 50-day moving average of $4.78 and a 200 day moving average of $4.71. The stock’s market cap is $356.72 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its earnings results on Thursday, May 5th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.05. The firm had revenue of $2.50 million for the quarter, compared to analyst estimates of $3.27 million. During the same quarter in the prior year, the company posted ($0.15) earnings per share. The company’s revenue for the quarter was up 908.1% on a year-over-year basis. Analysts forecast that Progenics Pharmaceuticals Inc. will post $0.12 EPS for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.